Carregant...
Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model
Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...
Guardat en:
| Publicat a: | Adv Healthc Mater |
|---|---|
| Autors principals: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/ https://ncbi.nlm.nih.gov/pubmed/33646600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|